A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

Inclusion Criteria:

- Has either clinically definite or laboratory-supported definite relapsing forms of MS
for at least 2 years

- Patients with SPMS or RRMS have documented medical history of relapse in the past
year or MRI-documented evidence of MS activity in the past year

- Has had an inadequate response or intolerability to interferon and/or glatiramer
acetate

- Is able and willing to undergo Gd administration and repeat MRI testing

Exclusion Criteria:

- Has primary progressive MS (PPMS)

- Any history of treatment with recombinant humanized monoclonal antibodies

- Has received treatment with immunosuppressant medications or experimental agents
within 3 months prior to the Baseline

- A history of opportunistic infection or the presence of any active infection within 3
months prior to Baseline

- Any history of congestive heart failure or currently has a pacemaker

- Has a known or suspected hypersensitivity to sulfonamides or any of the components of
the investigational drug

- Has any medical history or psychiatric condition that would impact outcome or study
participation

- Has other clinically significant abnormality on physical, neurological, laboratory,
or ECG examination as listed in the protocol during the Screening Phase